Aurinia Pharmaceuticals Inc. (AUPH)

5.87
0.01 0.17
NASDAQ : Health Technology
Prev Close 5.88
Open 5.90
Day Low/High 5.81 / 5.92
52 Wk Low/High 5.06 / 7.85
Volume 53.46K
Avg Volume 441.20K
Exchange NASDAQ
Shares Outstanding 78.45M
Market Cap 541.58M
EPS -0.80
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Relative Strength Alert For Aurinia Pharmaceuticals

Relative Strength Alert For Aurinia Pharmaceuticals

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Aurinia Reports Second Quarter 2019 Financial Results And Operational Highlights

Aurinia Reports Second Quarter 2019 Financial Results And Operational Highlights

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX:AUP) ("Aurinia" or the "Company"), a late- stage clinical biopharmaceutical company focused on advancing voclosporin in multiple indications, today reported financial results for the three and six months...

Aurinia Pharmaceuticals To Release Second Quarter 2019 Financial Results On August 6, 2019

Aurinia Pharmaceuticals To Release Second Quarter 2019 Financial Results On August 6, 2019

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) (the " Company") today announced that it will release its second quarter 2019 financial results on Tuesday, August 6, 2019, after the market closes.

AUPH Makes Notable Cross Below Critical Moving Average

AUPH Makes Notable Cross Below Critical Moving Average

In trading on Monday, shares of Aurinia Pharmaceuticals Inc crossed below their 200 day moving average of $6.26, changing hands as low as $6.20 per share. Aurinia Pharmaceuticals Inc shares are currently trading off about 1.6% on the day.

Aurinia Announces Further Strengthening Of The Senior Management Team

Aurinia Announces Further Strengthening Of The Senior Management Team

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH/TSX: AUP) (the "Company"), a late-stage clinical biopharmaceutical company with ongoing research in lupus nephritis ("LN"), today announced the appointments of Mr.

First Week Of AUPH August 16th Options Trading

First Week Of AUPH August 16th Options Trading

Investors in Aurinia Pharmaceuticals Inc saw new options become available this week, for the August 16th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the AUPH options chain for the new August 16th contracts and identified one put and one call contract of particular interest.

ILJIN Comments On Aurinia Pharmaceutical's Annual Meeting

ILJIN Comments On Aurinia Pharmaceutical's Annual Meeting

ILJIN SNT Co., Ltd.

Aurinia Shareholders Elect All Eight Directors At 2019 Annual General Meeting

Aurinia Shareholders Elect All Eight Directors At 2019 Annual General Meeting

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) ("Aurinia" or the "Company") is pleased to announce that shareholders of the Company (the "Shareholders") elected all eight of the Company's highly qualified director nominees at the Company's Annual...

ILJIN Chairman Issues Open Letter To Aurinia Shareholders

ILJIN Chairman Issues Open Letter To Aurinia Shareholders

ILJIN SNT Co., Ltd.

Aurinia Reminds Shareholders To Vote The YELLOW Proxy Prior To June 24 Deadline

Aurinia Reminds Shareholders To Vote The YELLOW Proxy Prior To June 24 Deadline

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) ("Aurinia" or the "Company") today reminded shareholders to vote in advance of the proxy voting deadline of 10:00 AM Mountain Time on Monday, June 24, 2019.

Aurinia Pharmaceuticals (AUPH) Shares Cross Below 200 DMA

Aurinia Pharmaceuticals (AUPH) Shares Cross Below 200 DMA

In trading on Tuesday, shares of Aurinia Pharmaceuticals Inc crossed below their 200 day moving average of $6.18, changing hands as low as $6.02 per share. Aurinia Pharmaceuticals Inc shares are currently trading down about 1.6% on the day.

Aurinia Issues Letter To Shareholders

Aurinia Issues Letter To Shareholders

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) (the " Company") today sent a letter to shareholders in connection with the Company's upcoming Annual General Meeting of Shareholders ("AGM") to be held on Wednesday, June 26, 2019.

Aurinia Pharmaceuticals To Present At Upcoming Investor Conferences

Aurinia Pharmaceuticals To Present At Upcoming Investor Conferences

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) (the " Company") today announced that Mr.

Aurinia Pharmaceuticals Announces Upcoming Annual General Meeting Of Shareholders

Aurinia Pharmaceuticals Announces Upcoming Annual General Meeting Of Shareholders

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) ("Aurinia" or the "Company"), today filed its Notice of Meeting and Management Information Circular.

First Week Of AUPH January 2020 Options Trading

First Week Of AUPH January 2020 Options Trading

Investors in Aurinia Pharmaceuticals Inc saw new options begin trading this week, for the January 2020 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 240 days until expiration the newly trading contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Aurinia Pharmaceuticals To Present At The RBC Capital Markets Global Healthcare Conference

Aurinia Pharmaceuticals To Present At The RBC Capital Markets Global Healthcare Conference

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) (the " Company") today announced that Mr.

Aurinia Reports First Quarter 2019 Financial Results And Recent Operational Highlights

Aurinia Reports First Quarter 2019 Financial Results And Recent Operational Highlights

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX:AUP) ("Aurinia" or the "Company") today reported financial results for the first quarter ended March 31, 2019 and provided an update on recent operational highlights.

Aurinia Recognizes World Lupus Day And Lupus Awareness Month With Activities Focused On Raising Awareness For Lupus Nephritis

Aurinia Recognizes World Lupus Day And Lupus Awareness Month With Activities Focused On Raising Awareness For Lupus Nephritis

In recognition of Lupus Awareness Month and World Lupus Day, Aurinia Pharmaceuticals Inc.

Aurinia Pharmaceuticals To Release First Quarter 2019 Financial Results On May 14, 2019

Aurinia Pharmaceuticals To Release First Quarter 2019 Financial Results On May 14, 2019

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) (the " Company") today announced that it will release its first quarter 2019 financial results on Tuesday, May 14, 2019, after the market closes.

Aurinia Further Strengthens Its Board Of Directors With The Appointment Of Dr. Daniel Billen

Aurinia Further Strengthens Its Board Of Directors With The Appointment Of Dr. Daniel Billen

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) ("Aurinia" or the "Company"), a clinical stage biopharmaceutical company focused on the global immunology market, today announced it has appointed Dr.

Aurinia Pharmaceuticals To Present At The 2019 Bloom Burton & Co. Healthcare Investor Conference

Aurinia Pharmaceuticals To Present At The 2019 Bloom Burton & Co. Healthcare Investor Conference

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) (the " Company") today announced that members of the management team will present a corporate overview at the 2019 Bloom Burton & Co.

Aurinia Announces Appointment Of Peter Greenleaf As Chief Executive Officer And Board Director And The Elevation Of Dr. George M. Milne, Jr. To Chairman Of The Board

Aurinia Announces Appointment Of Peter Greenleaf As Chief Executive Officer And Board Director And The Elevation Of Dr. George M. Milne, Jr. To Chairman Of The Board

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) ("Aurinia" or the "Company"), a late clinical-stage biopharmaceutical company focused on the global immunology market, today announced the appointment of Mr.

First Week Of May 17th Options Trading For Aurinia Pharmaceuticals (AUPH)

First Week Of May 17th Options Trading For Aurinia Pharmaceuticals (AUPH)

Investors in Aurinia Pharmaceuticals Inc saw new options begin trading this week, for the May 17th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the AUPH options chain for the new May 17th contracts and identified the following call contract of particular interest.

The Fed Decision Will Be a Market Mover No Matter What

The Fed Decision Will Be a Market Mover No Matter What

Computer algorithms will trigger volatility even if there is no surprise news.

Aurinia Reports Fourth Quarter And Full Year 2018 Financial Results And Operational Highlights

Aurinia Reports Fourth Quarter And Full Year 2018 Financial Results And Operational Highlights

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) ("Aurinia" or the "Company") today reported its financial results for the fourth quarter and year ended December 31, 2018.